疫苗股普跌 日本突現新冠病毒變異
格隆匯8月10日丨疫苗股領跌A股,其中,西藏藥業跌超8%,康泰生物跌近8%,復星醫藥、萬泰生物、華北製藥和未名醫藥跌超4%,沃森生物、智飛生物和華蘭生物跌超3%。有媒體稱,自6月中旬以來,日本疫情出現持續擴大之勢,多地刷新單日確診人數最高紀錄。日本國立傳染病研究所的研究小組宣佈一項分析結果稱,自今年6月以來,一種具有新型基因序列的新冠肺炎病毒已在日本全國範圍內傳播。關於日本新出現的病毒變異情況會對研製中的新冠疫苗造成影響,8月9日,疫苗專家陶黎納表示,現在研發的新冠疫苗都是基於去年12月至今年1月分離得到的病毒株。現在毒株已經出現一定變異,但是否需要調整疫苗還需觀察。另一位醫學專家稱不需要有太多擔心,因病毒的絕大多數變異都不會導致其免疫原性和抗原性的變化,不會影響疫苗的有效性。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.